Receptor dimerization - Rationale for the design of bivalent ligands

Current Topics in Medicinal Chemistry

Volumn 7, Issue 4, 2007, Pages 343-345

  Zhang, Ao ^a   Liu, Zhili ^a   Kan, Ying ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bivalent ligand; GPCR; Heterodimer; Homodimer; Monomer; Oligomerization

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; ADENOSINE A1 RECEPTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD28 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DELTA OPIATE RECEPTOR; DOPAMINE 1 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HEXOPRENALINE; HISTAMINE H2 RECEPTOR; KAPPA OPIATE RECEPTOR; KDN 21; METABOTROPIC RECEPTOR 1; MU OPIATE RECEPTOR; NATURAL KILLER CELL RECEPTOR; NORBINALTORPHIMINE; OPIATE ANTAGONIST; PENTRAXIN; SERUM AMYLOID P; SOMATOMEDIN B RECEPTOR; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN V2 RECEPTOR;

BINDING AFFINITY; BREAST CANCER; CARCINOGENESIS; CRYSTAL STRUCTURE; DIMERIZATION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; MALIGNANT TRANSFORMATION; OLIGOMERIZATION; PHARMACOPHORE; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 33847623714     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779941279     Document Type: Review

References (34)

1. Hazum, E.; Chang, K.-J., Cuatrecasas, P. Opiate (Enkephalin) receptors of neuroblastoma cells: Occurrence in clusters on the cell surface. Science, 1979, 206, 1077-1079.
2. Margeta-Mitrovic, M.; Jan, Y. N.; Jan, L. Y. A Trafficking Checkpoint Controls GABAB Receptor Heterodimerization, Neuron, 2000, 27, 97-106.
3. Fotiadis, D.; Liang, Y; Filipek, S; Saperstein, D. A.; Engel, A.; Palczewski, K. Atomic-force microscopy: Rhodopsin dimers in native disc membranes, Nature, 2003, 421(6919), 127-128.
4. Lee, S. P.; O'Dowd, B. F.; Ng, G. Y.; Varghese, G.; Akil, H.; Mansour, A.; Nguyen, T.; George, S. R. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell, Mol. Pharmacol, 2000, 58, 120-128.
5. Guo, W.; Shi, L. Javitch, J. A. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimers, J. Biol. Chem., 2003, 278 (7), 4385-4388.
6. (a) George, S. R.; O'Dowd, B. F.; Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery, Nat. Rev. Drug Discov., 2002, 1, 808-820;
7. (b) Bulenger, S.; Marullo, S., Bouvier, M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation, Trends Pharmacol. Sci., 2005, 26(3), 131-137.
8. (a) Heldin, C. H. Dimerization of cell surface receptors in signal transduction, Cell, 1995, 80, 213-223;
9. (b) Gupta, A.; Decaillot, F. M.; Devi, L. A. Targeting opioid receptor heterodimers: strategies for screening and drug development, AAPS J., 2006, 8(1), E153-9.
10. Sacher, M.; Di Bacco, A.; Lunin, V. V.; Ye, Z.; Wagner, J.; Gill, G.; Cygler, M. The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiation, Proc. Natl. Acad. Sci. USA, 2005, 102(51), 18326-18331.
11. De Mol, N. J.; Catalina, M. I.; Dekker, F. J.; Fischer, M. J. E., Heck, A. J. R.; Liskamp, R. M. J. Protein flexibility and ligand rigidity: A thermodynamic and kinetic study of ITAM-based ligand binding to Syk tandem SH2. ChemBioChem, 2005, 6(12), 2261-2270.
12. Ho, J. G. S.; Kitov, P. L; Paszkiewicz, E.; Sadowska, J.; Bundle, D. R.; Ng, K. K. S. Ligand-assisted Aggregation of Proteins: Dimerization of serum amyloid P component by bivalent ligands. J. Biol. Chem., 2005, 280, 31999-32008.
13. Dimasi, N.; Sawicki, M. W.; Reineck, L. A.; Li, Y.; Natarajan, K.; Margulies, D. H.; Mariuzza, R. A. Crystal Structure of the Ly49I Natural Killer Cell Receptor Reveals Variability in Dimerization Mode Within the Ly49 Family. J. Mol. Biol. 2002, 320(3), 573-585.
14. Yarden, Y. Biology of HER2 and Its Importance in Breast Cancer. Oncology, 2001, 61(Suppl. 2), 1-13.
15. Alroy, I.; Yarden, Y. Biochemistry of HER2 oncogenesis in breast cancer. Breast Disease, 2000, 11, 31-48.
16. Oosterwegel, M. A.; Greenwald, R. J.; Mandelbrot, D. A.; Lorsbach, R. B.; Sharpe, A. H. CTLA-4 and T cell activation. Curr. Opin. Immunol., 1999, 11, 294-300.
17. Najafian, N.; Sayegh, M. H, CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Investig. Drugs, 2000, 9, 2147-2157.
18. Schwartz, J. C. D.; Zhang, X.; Fedorov, A. A.; Nathenson, S. G.; Almo, S. C. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature, 2001, 410(6828), 604-607.
19. Mastellar, E. L.; Chuang, E.; Mullen, A. C.; Reiner, S. L.; Thompson, C. B. Structural analysis of CTLA-4 function in vivo, J. Immunol., 2000, 164, 5319-5327.
20. Jordan, B. A.; Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature, 1999, 399, 697-700.
21. Gomes, I.; Gupta, A.; Filipovska, J.; Szeto, H. H.; Pintar, J. E.; Devi, L. A. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. USA, 2004, 101, 5135-5139.
22. Gomes, I.; Jordan, B. A.; Gupta, A.; Trapaidze, N.; Nagy, V.; Devi, L. A. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy, J. Neurosci., 2000, 20, RC110.
23. Filizola, M.; Olmea, O.; Weinstein, H. Prediction of heterodimerization interfaces of G-protein coupled receptors with a new subtractive correlated mutation method. Protein Eng., 2002, 15, 881-885.
24. Filizola, M.; Weinstein, H. Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. Biopolymers, 2002, 66, 317-325.
25. Wang, D.; Sun, X.; Bohn, L. M.; Sadée, W. Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer. Mol. Pharmacol. 2005, 67, 2173-2184.
26. Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol Sci., 1989, 10, 230-235.
27. Pinder, R. M.; Brogden, R. N.; Speight, T. M.; Avery, G. S. Hexoprenaline: a review of its pharmacological properties and therapeutic efficacy with particular reference to asthma. Drugs, 1977, 14, 1-28.
28. Turnheim, K.; Kraupp, O. Pulmonary and systemic circulatory effects and b-adrenergic selectivity of hexoprenaline, salbutamol, oxyfedrine, and isoproterenol. Eur. J. Pharmacol., 1971, 15, 231-239.
29. Halazy, S. G-protein coupled receptors bivalent ligands and drug design. Expert Opin. Thera. Patents, 1999, 9(4), 431-446.
30. Messer, W. S., Jr. Bivalent ligands for G protein-coupled receptors. Curr. Pharm. Design, 2004, 10(17), 2015-2020.
31. Berube, G. Natural and synthetic biologically active dimeric molecules: Anticancer agents, anti-HIV agents, steroid derivatives and opioid antagonists. Curr. Med. Chem., 2006, 13(2), 131-154.
32. Portoghese, P. S. From Models to Molecules: Opioid Receptor Dimers, Bivalent Ligands, and Selective Opioid Receptor Probes. J. Med. Chem., 2001, 44(14), 2259-2269.
33. Daniels, D. J.; Lenard, N. R.; Etienne, C. L.; Law, P.-Y.; Roerig, S. C.; Portoghese, P. S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. USA, 2005, 102(52), 19208-19213.
34. Xie, Z.; Bhushan, R. G.; Daniels, D. J.; Portoghese, P. S. Interaction of bivalent ligand KDN21 with heterodimeric κ-δ opioid receptors in human embryonic kidney 293 cells. Mol. Pharmacol., 2005, 68(4), 1079-1086.